Fortress Biotech Inc
NASDAQ:FBIO
Fortress Biotech Inc
Revenue
Fortress Biotech Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fortress Biotech Inc
NASDAQ:FBIO
|
Revenue
$84.5m
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Fortress Biotech Inc's Revenue?
Revenue
84.5m
USD
Based on the financial report for Dec 31, 2023, Fortress Biotech Inc's Revenue amounts to 84.5m USD.
What is Fortress Biotech Inc's Revenue growth rate?
Revenue CAGR 5Y
26%
Over the last year, the Revenue growth was 12%. The average annual Revenue growth rates for Fortress Biotech Inc have been 23% over the past three years , 26% over the past five years .